Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab Sequential Therapy After Chemoradiation in Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
jRCT2041230133Phase 3Recruiting
- Sponsor
- GSK
- Start
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Dostarlimab arm with Placebo arm (2 arms). Primary endpoint: Event-free survival (EFS) by BICR. Started Mar 2024; status: recruiting.
02
Drugs
dostarlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2041230133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230133.